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SUMMARY
World-wide efforts will soon result in the identification and decoding
of all 70,000 human genes. Many of these genes are involved in diseases as a
result of mutations, i.e., changes in their DNA-based code, leading to
functional changes in the corresponding proteins. Technologies have emerged
that can analyze genes for such mutations from small samples of blood or
buccal swabs. However, since many disease genes arelarge, and the mutations
can be anywhere over the entire length of the gene, methods are needed that
can do this accurately, yet at low cost. The development and evaluation of
such a method is the subject of this thesis.
In Chapter 1, criteria for mutation detection in both the clinical genetic
diagnostic and genetic epidemiologic setting are discussed, and some of the
currently most frequently used mutation detection methods are reviewed. The
method that was developed in the context of this thesis is called Two-
Dimensional Gene Scanning (TDGS). The system is based on the preparation
of multiple target fragments from genomic DNA in a parallel fashion (PCR
megaplex), followed by the resolution of the fragment mixture by two-
dimensional DNA electrophoresis. This electrophoresis component of TDGS
consists of a size separation of all amplicons (representing the entire gene),
followed by sequence-specific separation in a denaturing gradient gel.
Together these two steps allow for the detection of all possible mutational
variants, except very large chromosomal changes that can easily be detected
by other means.
Chapter 2 describes the design and evaluation of a TDGS test for a
large human disease gene, the retinoblastoma tumor suppressor gene R.81. The
RBI gene comprises 27 exons, spanning over 200 kb in genomic length.
Mutations have been found scattered throughout the gene, which makes
mutation scanning an immense task. It was demonstrated that TDGS greatly
simplifies this task and provides for a cost-effective way of gene mutation
scanning.
To evaluate TDGS for other genes, a solution had to be found for the
test design. The design of TDGS tests is not trivial. First, primers have to be
designed that are compatible in an extensive multiplex reaction, and, in
addition, are suitable for denaturing gradient gel electrophoresis (DGGE). This
means that primers, one of which is attached to a GC-clamp, amplify a
fragment that behaves as a one-domain fragment in a denaturing gradient gel.
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Second, primers have to be designed in such a way that there is no overlap
between the resulting fragments in the 2-D gel. These critical issues have
prompted the development of a computer program that automatically designs
complete TDGS tests for any gene in minutes, rather than days or weeks of
trial and error (Chapter 3).
Using this computer program, the general applicability of TDGS could
be tested by analyzing different genes with their own unique set of
characteristics. Chapter 4 describes a TDGS test for a relatively GC-rich gene,
the tumor suppressor gene TP53, which is frequently mutated in human
cancers. From this work it was learnt how to deal with GC-rich genes in the
context of TDGS.
In Chapter 5, the development of a TDGS test for the most critical
regions of the mitochondrial genome is described. The mitochondrial genome
does not contain introns, and is rife with secondary structures on the DNA
level. Both these issues play a role in the design of a TDGS-based mutational
scanning test. In addition, the occurrence of heteroplasmy in mitochondrial
DNA requires a test that can detect low (i.e., 1 %) frequencies of mutant
alleles. This can be of use in prognostic testing, e.g., when tumor tissues are
utalyzed for prognostic markers in a subset of cells. The results were
satisfactory in that a mtDNA test was obtained capable of addressing all these
difficulties.
The last TDGS test created and evaluated in the context of this thesis is
a test for the breast and ovarian cancer susceptibility gene BRCAI (Chapter 6).
The BRCAI gene is identical to the RBI gene in many respects, such as
relatively low GC-content, many exons encompassing a large genomic region,
and a scattered mutational spectrum. However, BRCAI shows the problems
that arise when a gene is rich in polymorphic sites. Since the significance of
many of the observed variations is not known, and new mutations are found
continuously (so far, over 300 different mutations have been described for this
gene), it is difficult to ascribe a new variation as a pathogenic mutation. In
Chapter 6 it is demonstrated that TDGS can distinguish between known
mutations and polymorphisms.
In Chapter 7, various present and future applications of gene variation
scanning are reviewed. For all these applications TDGS could become the
method of choice. Other competitive and ultra-high throughput methods,
however, are under development. To illustrate the power of TDGS already in




































have been worked out. The first involved the creation of a comprehensive
inventory of all possible gene differences between humans. In principle, such a
project would provide the tools for a wide range of applications, including
individual genotyping to predict efficacy and toxicity of drugs, disease
susceptibility and prognosis. A rough calculation showed that with TDGS as
the method of choice (supplemented with some commercially available
automated equipment), such a "human genetic variation program" could be
completed within 5 years at a cost of US$300,000,000. This is relatively
modest compared to the 15-year US$3,000,000,000 human genome project.
The second example involved the use of TDGS for a comprehensive
genome-wide disease susceptibility test. Based on the assumption that there
are about 100 major human diseases, each of which involves 5-10 genes, a
complete "genetic disease passport" would require the analysis of 500 to 1,000
genes. Using TDGS, such a genome-wide susceptibility test could be
performed for US$ 1,500-3,000.
If anything, these two examples illustrate the revolution witnessed
during the last decade, in which human genomic medicine has transformed
itself from a virtual into a practical reality.
1 1 4
T J J
